Investment Thesis
Nuo Therapeutics exhibits severe financial distress with negative stockholders' equity of -$419.6K, indicating the company is technically insolvent. Despite 124.3% revenue growth, the company is burning cash at an alarming rate (-$673.9K free cash flow) while maintaining massive operating losses (-87.4% margin), and with only $514.8K in cash reserves against $2.3M in liabilities, the company faces imminent solvency crisis.
Strengths
- Strong revenue growth of 124.3% YoY demonstrates market demand for products
- Gross margin of 69.0% indicates pricing power and product viability at production level
- No long-term debt reduces refinancing risk in near term
Risks
- Negative stockholders' equity of -$419.6K indicates technical insolvency and potential shareholder dilution
- Severe cash burn of -$673.9K FCF with only $514.8K cash on hand provides less than one quarter of runway
- Operating losses of -$1.9M despite revenue growth indicate inability to achieve operational efficiency
- Liabilities of $2.3M exceed total assets of $1.9M by $400K creating balance sheet crisis
- Negative operating cash flow of -$442.3K shows business cannot fund operations internally
Key Metrics to Watch
- Cash position depletion rate and runway to insolvency
- Operating loss trajectory and path to profitability timeline
- Revenue growth sustainability and gross margin maintenance
- Capital requirements and dilution from equity financing
- Working capital management and accounts payable/receivable trends
Financial Metrics
Revenue
2.2M
Net Income
-1.9M
EPS (Diluted)
$-0.03
Free Cash Flow
-673.9K
Total Assets
1.9M
Cash
514.8K
Profitability Ratios
Gross Margin
69.0%
Operating Margin
-87.4%
Net Margin
-87.2%
ROE
N/A
ROA
-100.3%
FCF Margin
-30.4%
Balance Sheet & Liquidity
Current Ratio
1.16x
Quick Ratio
1.00x
Debt/Equity
N/A
Debt/Assets
121.8%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T10:24:11.029208 |
Data as of: 2025-09-30 |
Powered by Claude AI